Literature DB >> 21606553

Limited-angle x-ray luminescence tomography: methodology and feasibility study.

C M Carpenter1, G Pratx, C Sun, L Xing.   

Abstract

X-ray luminescence tomography (XLT) has recently been proposed as a new imaging modality for biological imaging applications. This modality utilizes phosphor nanoparticles which luminesce near-infrared light when excited by x-ray photons. The advantages of this modality are that it uniquely combines the high sensitivity of radioluminescent nanoparticles and the high spatial localization of collimated x-ray beams. Currently, XLT has been demonstrated using x-ray spatial encoding to resolve the imaging volume. However, there are applications where the x-ray excitation may be limited by geometry, where increased temporal resolution is desired, or where a lower dose is mandatory. This paper extends the utility of XLT to meet these requirements by incorporating a photon propagation model into the reconstruction algorithm in an x-ray limited-angle (LA) geometry. This enables such applications as image-guided surgery, where the ability to resolve lesions at depths of several centimeters can be the key to successful resection. The hybrid x-ray/diffuse optical model is first formulated and then demonstrated in a breast-sized phantom, simulating a breast lumpectomy geometry. Both numerical and experimental phantoms are tested, with lesion-simulating objects of various sizes and depths. Results show localization accuracy with median error of 2.2 mm, or 4% of object depth, for small 2-14 mm diameter lesions positioned from 1 to 4.5 cm in depth. This compares favorably with fluorescence optical imaging, which is not able to resolve such small objects at this depth. The recovered lesion size has lower size bias in the x-ray excitation direction than the optical direction, which is expected due to the increased optical scatter. However, the technique is shown to be quite invariant in recovered size with respect to depth, as the standard deviation is less than 2.5 mm. Sensitivity is a function of dose; radiological doses are found to provide sufficient recovery for µg ml(-1) concentrations, while therapy dosages provide recovery for ng ml(-1) concentrations. Experimental phantom results agree closely with the numerical results, with positional errors recovered within 8.6% of the effective depth for a 5 mm object, and within 5.2% of the depth for a 10 mm object. Object-size median error is within 2.3% and 2% for the 5 and 10 mm objects, respectively. For shallow-to-medium depth applications where optical and radio-emission imaging modalities are not ideal, such as in intra-operative procedures, LAXLT may be a useful tool to detect molecular signatures of disease.

Entities:  

Mesh:

Year:  2011        PMID: 21606553      PMCID: PMC4132056          DOI: 10.1088/0031-9155/56/12/003

Source DB:  PubMed          Journal:  Phys Med Biol        ISSN: 0031-9155            Impact factor:   3.609


  34 in total

1.  Real-time vital optical imaging of precancer using anti-epidermal growth factor receptor antibodies conjugated to gold nanoparticles.

Authors:  Konstantin Sokolov; Michele Follen; Jesse Aaron; Ina Pavlova; Anais Malpica; Reuben Lotan; Rebecca Richards-Kortum
Journal:  Cancer Res       Date:  2003-05-01       Impact factor: 12.701

2.  Optical properties of normal and diseased human breast tissues in the visible and near infrared.

Authors:  V G Peters; D R Wyman; M S Patterson; G L Frank
Journal:  Phys Med Biol       Date:  1990-09       Impact factor: 3.609

3.  Tomographic molecular imaging of x-ray-excitable nanoparticles.

Authors:  Guillem Pratx; Colin M Carpenter; Conroy Sun; Ravi P Rao; Lei Xing
Journal:  Opt Lett       Date:  2010-10-15       Impact factor: 3.776

4.  Frequency-domain fluorescent diffusion tomography: a finite-element-based algorithm and simulations.

Authors:  H Jiang
Journal:  Appl Opt       Date:  1998-08-01       Impact factor: 1.980

Review 5.  External hypofractionated whole-breast radiotherapy: now where does accelerated partial breast irradiation stand?

Authors:  Anusheel Munshi
Journal:  J Cancer Res Ther       Date:  2007 Oct-Dec       Impact factor: 1.805

6.  Medical decision making regarding computed tomographic radiation dose and associated risk: the patient's perspective.

Authors:  Elaine M Caoili; Richard H Cohan; James H Ellis; Jonathan Dillman; Matthew J Schipper; Isaac R Francis
Journal:  Arch Intern Med       Date:  2009-06-08

7.  Local failure is responsible for the decrease in survival for patients with breast cancer treated with conservative surgery and postoperative radiotherapy.

Authors:  A Fortin; M Larochelle; J Laverdière; S Lavertu; D Tremblay
Journal:  J Clin Oncol       Date:  1999-01       Impact factor: 44.544

8.  Image-guided oncologic surgery using invisible light: completed pre-clinical development for sentinel lymph node mapping.

Authors:  Eiichi Tanaka; Hak Soo Choi; Hirofumi Fujii; Moungi G Bawendi; John V Frangioni
Journal:  Ann Surg Oncol       Date:  2006-09-29       Impact factor: 5.344

Review 9.  Imaging in the era of molecular oncology.

Authors:  Ralph Weissleder; Mikael J Pittet
Journal:  Nature       Date:  2008-04-03       Impact factor: 49.962

Review 10.  Accelerated partial breast irradiation: technically feasible but who will benefit?

Authors:  Gillian Ross
Journal:  Breast Cancer Res       Date:  2005-04-05       Impact factor: 6.466

View more
  15 in total

1.  X-ray luminescence computed tomography imaging based on X-ray distribution model and adaptively split Bregman method.

Authors:  Dongmei Chen; Shouping Zhu; Xu Cao; Fengjun Zhao; Jimin Liang
Journal:  Biomed Opt Express       Date:  2015-06-23       Impact factor: 3.732

2.  X-ray-induced shortwave infrared luminescence computed tomography.

Authors:  Xianjin Dai; Kai Cheng; Wei Zhao; Lei Xing
Journal:  Opt Lett       Date:  2019-10-01       Impact factor: 3.776

3.  High-speed X-ray-induced luminescence computed tomography.

Authors:  Xianjin Dai; Kai Cheng; Wei Zhao; Lei Xing
Journal:  J Biophotonics       Date:  2020-06-23       Impact factor: 3.207

4.  Bright X-ray and up-conversion nanophosphors annealed using encapsulated sintering agents for bioimaging applications.

Authors:  Hongyu Chen; Fenglin Wang; Thomas Moore; Bin Qi; Dino Sulejmanovic; Shiou-Jyh Hwu; O Thompson Mefford; Frank Alexis; Jeffrey N Anker
Journal:  J Mater Chem B       Date:  2017-06-13       Impact factor: 6.331

5.  Cone Beam X-ray Luminescence Computed Tomography Based on Bayesian Method.

Authors:  Guanglei Zhang; Fei Liu; Jie Liu; Jianwen Luo; Yaoqin Xie; Jing Bai; Lei Xing
Journal:  IEEE Trans Med Imaging       Date:  2016-08-26       Impact factor: 10.048

6.  Magnetic and optical properties of multifunctional core-shell radioluminescence nanoparticles.

Authors:  Hongyu Chen; Daniel C Colvin; Bin Qi; Thomas Moore; Jian He; O Thompson Mefford; Frank Alexis; John C Gore; Jeffrey N Anker
Journal:  J Mater Chem       Date:  2012-07-07

Review 7.  Nanotechnologies for noninvasive measurement of drug release.

Authors:  Thomas Moore; Hongyu Chen; Rachel Morrison; Fenglin Wang; Jeffrey N Anker; Frank Alexis
Journal:  Mol Pharm       Date:  2013-11-26       Impact factor: 4.939

8.  Nanoscintillator-mediated X-ray inducible photodynamic therapy for in vivo cancer treatment.

Authors:  Hongmin Chen; Geoffrey D Wang; Yen-Jun Chuang; Zipeng Zhen; Xiaoyuan Chen; Paul Biddinger; Zhonglin Hao; Feng Liu; Baozhong Shen; Zhengwei Pan; Jin Xie
Journal:  Nano Lett       Date:  2015-03-12       Impact factor: 11.189

Review 9.  Advances in functional X-ray imaging techniques and contrast agents.

Authors:  Hongyu Chen; Melissa M Rogalski; Jeffrey N Anker
Journal:  Phys Chem Chem Phys       Date:  2012-10-21       Impact factor: 3.676

10.  Monitoring pH-triggered drug release from radioluminescent nanocapsules with X-ray excited optical luminescence.

Authors:  Hongyu Chen; Thomas Moore; Bin Qi; Daniel C Colvin; Erika K Jelen; Dale A Hitchcock; Jian He; O Thompson Mefford; John C Gore; Frank Alexis; Jeffrey N Anker
Journal:  ACS Nano       Date:  2013-01-09       Impact factor: 15.881

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.